GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...

GSK has agreed to pay up to $2.2 billion to resolve approximately 80,000 lawsuits brought by users of Zantac who claimed the heartburn drug caused their cancer. The agreement frees the British ...

British pharmaceutical company GSK said on Wednesday that it has agreed to pay $2.3 billion to put an end to lawsuits in ... to pay $70 million to settle a separate Zantac case with US laboratory ...

GSK, Sanofi and Boehringer Ingelheim. Last month, Sanofi reached an agreement in principle to settle 4,000 lawsuits linking Zantac to cancer. Sanofi did not disclose the financial terms of the ...

Pfizer Inc. has agreed to settle more than 10,000 cases accusing ... The deal is likely to reassure investors, who have seen other Zantac makers, including GSK Plc and Sanofi, sign settlements.

May 8 (Reuters) - Pfizer (PFE.N), opens new tab has agreed to settle more than 10,000 lawsuits about cancer risks related to the now discontinued heartburn drug Zantac, Bloomberg News reported on ...

GSK (GSK.L), opens new tab has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer ...

GSK has reached agreements with 10 plaintiff firms to settle around 80,000 state court product liability cases related to its heartburn medication, Zantac, for $2.2 billion. The agreements involve ...